ReviewInfection2026
Beyond granulomatous amoebic encephalitis: changing epidemiology and an expanding spectrum of non-flagellated amoebic CNS infection in India.
Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGranulomatous amoebic encephalitis (GAE) is the conventional label for central nervous system (CNS) infection caused principally by Acanthamoeba spp. and Balamuthia mandrillaris, but contemporary disease encompasses meningitic, focal, vascular, brainstem, and spinal phenotypes that extend beyond the classical description. This narrative review examines the changing epidemiology, clinical spectrum, diagnosis, and management of non-flagellated amoebic CNS infection in India.
methodsWe narratively synthesised published Indian case reports, case series, molecular studies, surveillance investigations, and relevant environmental and epidemiological evidence on CNS infections caused by Acanthamoeba, Balamuthia, Vermamoeba, and Sappinia.
resultsHistorically, disease in India was recognised mainly through sporadic reports of Acanthamoeba GAE, with occasional confirmed Balamuthia infection. More recent reports from several regions, particularly Karnataka and West Bengal, together with systematic surveillance in Kerala, suggest a substantial expansion in recognised disease. Contemporary Indian experience increasingly includes apparently immunocompetent patients and a broader neurological spectrum, including chronic meningitis mimicking CNS tuberculosis, focal abscess, parkinsonism, myelopathy, and rhombencephalomyelitis; relapse after apparent recovery has also been documented. Water-related exposures and use of nonchlorinated domestic water have emerged as potentially important epidemiological associations. Molecular studies confirm that Acanthamoeba is the dominant contemporary organism, whereas Balamuthia remains rare; reported Vermamoeba infections warrant cautious interpretation, and no Indian Sappinia CNS infection was identified. Treatment remains empirical, multidrug, and poorly standardised.
conclusionThe recent Indian experience probably reflects substantial diagnostic discovery superimposed on a possible true increase in environmentally acquired Acanthamoeba CNS infection. Organism-specific surveillance, improved molecular diagnosis, and prospective treatment data are needed to define the true burden, transmission pathways, and optimal management of these infections.
Indexed as
Identifiers
42828622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.